In this episode, the discussion revolves around the 340B Drug Pricing Program, its origins, current issues, and potential reforms. Rena Conti provides insights into how the program, initially designed to help underinsured patients, has expanded and been misused, leading to significant concerns about its effectiveness. The conversation also touches on emerging business models that exploit the program, legislative challenges, and the need for bipartisan support to address these issues. Ultimately, the episode emphasizes the importance of ensuring access to affordable healthcare for vulnerable populations.